ArticlePloS one2024

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

Supachaya Sriphoosanaphan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.